The mechanism of vascular calcification - a systematic review

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Karwowski, Wojciech ^a   Naumnik, Beata ^b   Szczepański, Marek ^b   Myśliwiec, Michał ^b  

^a District General Hospital Bialystok   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Estrogens; Menopause; Osteoporosis; Raloxifene; Vascular calcification

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALKALINE PHOSPHATASE; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; EPLERENONE; ESTRADIOL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OMEGA 3 FATTY ACID; OSTEOCALCIN; PARATHYROID HORMONE; RALOXIFENE; VITAMIN D RECEPTOR; WARFARIN;

ADVENTITIA; ARTERY CALCIFICATION; ATHEROSCLEROTIC PLAQUE; BIOMINERALIZATION; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; BONE MINERALIZATION; BONE TISSUE; CALCIFICATION; CALCINOSIS; CARDIOVASCULAR DISEASE; CELL STRUCTURE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CRYSTALLIZATION; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOCRINE DISEASE; ESTROGEN THERAPY; HUMAN; HYPERPHOSPHATEMIA; IN VITRO STUDY; KIDNEY FAILURE; METABOLIC DISORDER; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW;

EID: 84855274336     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.882181     Document Type: Review

References (119)

1. Jeziorska M, McCollum C, Wooley DE: Observations on bone formation and remodeling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch, 1998; 433: 559-65
2. Budoff MJ, Yu D, Nasir K et al: Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J, 2005; 149: 695-700
3. Block GA, Spiegel DM, Ehrlich J et al: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int, 2005; 68: 1815-24
4. Wang L, Jerosch-Herold M, Jacobs DR Jr et al: Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi Ethnic Study of Atherosclerosis). J Am Coll Cardiol, 2006; 48: 1018-26
5. Ehara S, Kobayashi Y, Yoshiyama M et al: Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation, 2004; 110: 3424-29
6. Virmani R, Burke AP, Farb A, Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol, 2006; 47(Suppl.): C13-18
7. Huang H, Virmani R, Younis H et al: The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation, 2001; 103: 1051-56
8. Vengrenyuk Y, Carlier S, Xanthos S et al: A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci USA, 2006; 103: 14678-83
9. Bild DE, Detrano R, Peterson D et al: Ethnic Differences in Coronary Calcification: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2005; 111: 1313-20
10. Pohle K, Maffert R, Ropers D et al: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation, 2001; 104: 1927-32
11. Schurgin S, Rich S, Mazzone T: Increased Prevalence of Significant Coronary Artery Calcification in Patients With Diabetes. Diabetes Care, 2001; 24: 335-38
12. Goodman WG, Goldin J, Kuizon BD et al: Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis. N Engl J Med, 2000; 342: 1478-83
13. Iribarren C, Sidney S, Sternfeld B, Browner WS: Calcification of the Aortic Arch: Risk Factors and Association with Coronary Heart Disease, Stroke, and Peripheral Vascular Disease. JAMA, 2000; 283: 2810-15
14. Leoncini G, Ratto E, Viazzi F et al: Increased Ambulatory Arterial Stiffness Index Is Associated With Target Organ Damage in Primary Hypertension. Hypertension, 2006; 48: 397-403
15. Wang L, Jerosch-Herold M, Jacobs DR Jr et al: Coronary Artery Calcification and Myocardial Perfusion in Asymptomatic Adults The MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol, 2006; 48: 1018-26
16. Hasdai D, Gibbons RJ, Holmes DR et al: Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation, 1997; 96: 3390-95
17. Abedin M, Tintut Y, Demer LL: Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol, 2004; 24: 1161-70
18. Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol, 2004; 165(5): 625-30
19. Anderson HC, Sipe JB, Hessle L et al: Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol, 2004; 164(3): 841-47
20. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res, 1999;84: 166-78
21. Speer MY, McKee MD, Guldberg RE et al: Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med, 2002; 196: 1047-55
22. Tanimura A, McGregor DH, Anderson HC: Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med, 1983; 172: 173-77
23. Bostrom K, Watson KE, Horn S et al: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest, 1993; 91: 1800-9
24. Steitz SA, Speer MY, Curinga G et al: Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res, 2001; 89: 1147-54
25. Ikeda T, Shirasawa T, Esaki Y et al: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest, 1993; 92: 2814-20
26. Tintut Y, Alfonso Z, Saini T et al: Multilineage potential of cells from the artery wall. Circulation, 2003; 108: 2505-10
27. Reynolds JL, Joannides AJ, Skepper JN et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol, 2004; 15: 2857-67
28. Somers P, Knaapen M, Kockx M et al: Histological evaluation of autophagic cell death in calcified aortic valve stenosis. J Heart Valve Dis, 2006; 15(1): 43-47
29. Nicholls SJ, Tuzcu EM, Wolski K et al: Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol, 2007; 49: 263-70
30. Callister TQ, Raggi P, Cooil B et al: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med, 1998; 339: 1972-78
31. Bas A, Lopez I, Perez J et al: Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res, 2006; 21: 484-90
32. Linda L. Demer and Yin Tintut. Vascular Calcification: Pathobiology of a Multifaceted Disease. Circulation, 2008; 117: 2938-48
33. Pohle K, Maffert R, Ropers D, Moshage et al: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation, 2001; 104: 1927-32
34. Moura LM, Ramos SF, Zamorano JL et al: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol, 2007; 49: 554-61
35. Son BK, Kozaki K, Iijima K et al: Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res, 2006; 98: 1024-31
36. Schmermund A, Achenbach S, Budde T et al: Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation, 2006; 113: 427-37
37. Cowell SJ, Newby DE, Prescott RJ et al: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med, 2005; 352: 2389-97
38. Tintut Y, Parhami F, Bostrom K et al: cAMP stimulates osteoblast-like differentiation of calcifying vascular cells: potential signaling pathway for vascular calcification. J Biol Chem, 1998; 273: 7547-53
39. Proudfoot D, Davies JD, Skepper JN et al: Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation, 2002; 106: 3044-50
40. Tintut Y, Patel J, Territo M et al: Monocyte/macrophage regulation of vascular calcification in vitro. Circulation, 2002; 105: 650-55
41. Abedin M, Lim J, Tang TB et al: N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res, 2006; 98: 727-29
42. Parhami F, Basseri B, Hwang J et al: High-density lipoprotein regulates calcification of vascular cells. Circ Res, 2002; 91: 570-76
43. Watson KE, Bostrom K, Ravindranath R et al: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest, 1994; 93: 2106-13
44. Garfinkel A, Tintut Y, Petrasek D et al: Pattern formation by vascular mesenchymal cells. Proc Natl Acad Sci USA, 2004; 101: 9247-50
45. Otto CM, Kuusisto J, Reichenbach DD et al: Characterization of the early lesion of "degenerative" valvular aortic stenosis. Histological and immunohistochemical studies. Circulation, 1994; 90: 844-53
46. Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M: T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart, 2002; 88: 348-51
47. Rajamannan NM, Subramaniam M, Rickard D et al: Human aortic valve calcification is associated with an osteoblast phenotype. Circulation, 2003: 107: 2181-84
48. Mohler ER III, Chawla MK, Chang AW et al: Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis, 1999; 8: 254-60
49. Mohler ER III, Gannon F, Reynolds C et al: Bone formation and inflammation in cardiac valves. Circulation, 2001; 103: 1522-28
50. Rajamannan NM, Subramaniam M, Stock SR et al: Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesteroleamic aortic valve. Heart, 2005; 91: 806-10
51. Gkizas S, Koumoundourou D, Sirinian X et al: Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. Eur J Pharmacol, 2010; 642(1-3): 107-12
52. Schafer A, Vogt C, Fraccarollo D et al: Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J Physiol Pharmacol, 2010; 61(1): 45-52
53. Ix JH, Chertow GM, Shlipak MG et al: Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation, 2007; 115: 2533-39
54. Willens HJ, Chirinos JA, Schob A et al: The relation between mitral annular calcification and mortality in patients undergoing diagnostic coronary angiography. Echocardiography, 2006; 23: 717-22
55. Reaven PD, Sacks J: Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia, 2005; 48: 379-85
56. Okuno S, Ishimura E, Kitatani K et al: Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis, 2007; 49: 417-25
57. London GM, Guerin AP, Marchais SJ et al: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant, 2003; 18: 1731-40
58. Nelson RG, Gohdes DM, Everhart JE et al: Lower-extremity amputations in NIDDM: 12-yr follow-up study in Pima Indians. Diabetes Care, 1988; 11: 8-16
59. Cheng SL, Shao JS, Charlton-Kachigian N et al: MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem, 2003; 278: 45969-77
60. Bidder M, Shao JS, Charlton-Kachigian N et al: Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem, 2002; 277: 44485-96
61. Chen NX, Duan D, O'Neill KD, Moe SM: High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant, 2006; 21(12): 3435-42
62. Neven E, Dauwe S, De Broe ME et al: Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int, 2007; 72: 574-81
63. Graciolli FG, Neves KR, dos Reis LM et al: Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant, 2009; 24(5): 1416-21
64. Adeney KL, Siscovick DS, Ix JH et al: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol, 2009; 20(2): 381-87
65. Li X, Yang HY, Giachelli CM: BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis, 2008; 199(2): 271-77
66. Basalyga DM, Simionescu DT, Xiong W et al: Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation, 2004; 110: 3480-87
67. Chung AW, Yang HH, Sigrist MK et al: Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesisin diabetes and chronic kidney disease. Cardiovasc Res, 2009; 84(3): 494-504
68. Lee JS, Basalyga DM, Simionescu A et al: Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am J Pathol, 2006; 168: 490-98
69. Qin X, Corriere MA, Matrisian LM, Guzman RJ: Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol, 2006; 26: 1510-16
70. Pereira L, Lee SY, Gayraud B et al: Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA, 1999; 96: 3819-23
71. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol, 1998; 18: 1400-7
72. Bostrom K, Tsao D, Shen S et al: Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem, 2001; 276: 14044-52
73. Chen NX, Duan D, O'Neill KD, Moe SM: High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant, 2006; 21: 3435-42
74. Taki K, Takayama F, Tsuruta Y, Niwa T: Oxidative stress, advanced gly cation end product, and coronary artery calcification in hemodialysis patients. Kidney Int, 2006; 70: 218-24
75. Benet-Pages A, Orlik P, Strom TM et al: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet, 2005; 14: 385-90
76. Stubbs J, Liu S, Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial, 2007; 20: 302-8
77. Ichikawa S, Lyles KW, Econs MJ: A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab, 2005; 90: 2420-23
78. Stubbs JR, Liu S, Tang W et al: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol, 2007; 18: 2116-24
79. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int, 2002; 62: 245-52
80. Russo D, Miranda I, Ruocco et al: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int, 2007; 72: 1255-61
81. Tokumoto M, Mizobuchi M, Finch JL et al: Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol, 2009; 29(6): 582-91
82. Koz C, Baysan O, Yokusoglu M et al: The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit, 2009; 15(7): PI 41-45
83. Ketteler M, Bongartz P, Westenfeld R et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet, 2003; 361(9360): 827-33
84. Coen G, Pierantozzi A, Spizzichino D et al: Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol, 2010; 11: 10
85. Wu-Wong JR, Nakane M, Ma J et al: Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis, 2006; 186: 20-28
86. Aihara K, Azuma H, Akaike M et al: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem, 2004; 279: 35798-802
87. Zehnder D, Bland R, Chana RS et al: Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol, 2002; 13: 621-29
88. Martinesi M, Bruni S, Stio M et al: 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int, 2006; 30: 365-75
89. Timms PM, Mannan N, Hitman GA et al: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM, 2002; 95: 787-96
90. Haffner D, Hocher B, Muller D et al: Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens, 2005; 23: 1067-75
91. Bas A, Lopez I, Perez J et al: Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res, 2006; 21: 484-90
92. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation, 1998; 98: 1302-6
93. Jono S, Nishizawa Y, Shioi A, Morii H: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 1997; 17: 1135-42
94. Reynolds JL, Joannides AJ, Skepper JN et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol, 2004; 15: 2857-67
95. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens, 2005; 14: 525-31
96. Shao JS, Cheng SL, Charlton-Kachigian N et al: Teriparatide [human parathyroid hormone-(1-34)] inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor deficient mice. J Biol Chem, 2003; 278: 50195-202
97. Neves KR, Graciolli FG, dos Reis LM et al: Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int, 2007; 71: 1262-70
98. Langub MC, Monier-Faugere MC, Wang G et al: Administration of PTH(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology, 2003; 144: 1135-38
99. Nakajima K, Nohtomi K, Sato M et al: PTH(7-84) inhibits PTH(1-34)induced 1,25-(OH)2D3 production in murine renal tubules. Biochem Biophys Res Commun, 2009; 381(2): 283-87
100. Shoji T, Shinohara K, Kimoto E et al: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant, 2004; 19: 179-84
101. Barreto DV, Barreto FC, Liabeuf S et al: Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol, 2009; 4(6): 1128-35
102. Ogawa T, Ishida H, Akamatsu M et al: Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels, 2010; 25(1): 1-6
103. Seremak-Mrozikiewicz A, Drews K, Mrozikiewicz PM et al: Correlation of vitamin D receptor gene (VDR) polymorphism with osteoporotic changes in Polish postmenopausal women. Neuro Endocrinol Lett, 2009; 30(4): 540-46
104. Ravani P, Malberti F, Tripepi G et al: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int, 2009; 75: 88-95
105. Kooienga L, Fried L, Scragg R et al: The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis, 2009; 53: 408-16
106. KDIGO Clinical practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int, 2009; 76(Suppl): 113
107. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcifcation in uremic rats. Kidney Int, 2007; 72: 709-15
108. Das UN: Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids. Exp Biol Med, 2002; 227(2): 88-93
109. Mackey RH, Kuller LH, Sutton-Tyrrell K et al: Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch Intern Med, 2005; 165: 510-15
110. Manson J, Allison M, Rossouw JE et al: Estrogen Therapy and Coronary Artery Calcification. N Engl J Med, 2007; 356: 2591-602
111. Jeon GH, Kim SH, Yun SC et al: Association between serum estradiol level and coronary artery calcification in postmenopausal women. Menopause, 2010; 17(5): 902-7
112. Takahashi K, Ohmichi M, Yoshida M et al: Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol, 2003; 178(2): 319-29
113. Rzewuska-Lech E, Jayachandran M, Fitzpatrick LA, Miller VM: Differential effects of 17b-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. Am J Physiol Endocrinol Metab, 2005; 289: E105-12
114. Miller VM, Black DM, Brinton EA et al: Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. J Cardiovasc Transl Res, 2009; 2(3): 228-39
115. Wong CM, Yung LM, Leung FP et al: Raloxifene protects endothelial cell function against oxidative stress. Br J Pharmacol, 2008; 155(3): 326-34
116. Shargorodsky M, Boaz M, Luckish A et al: Osteoprotegerin as an independent marker of subclinical atherosclerosis inosteoporotic postmenopausal women. Atherosclerosis, 2009; 204(2): 608-11
117. Helas S, Goettsch C, Schoppet M et al: Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol, 2009; 175(2): 473-78
118. Choi BG, Vilahur G, Cardoso L et al: Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. Eur J Clin Invest, 2008; 38(4): 211-17
119. Fernández-García D, Muñoz-Torres M, Mezquita-Raya P et al: Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest, 2008; 31(5): 416-21